Teva Study Reveals Stark Diagnosis Gap in Young Adults with Mood Disorders and TD
Event summary
- Teva's IMPACT-TD Registry found only 23% of young adults (18-29) with mood disorders and TD symptoms formally diagnosed, despite 85% experiencing moderate to severe impact.
- Study included 611 participants, with 211 having mood disorders and TD, highlighting significant diagnostic delays averaging 3.5 years.
- Data presented at the 2026 American Psychiatric Association Annual Meeting (May 16-20, 2026).
- Psychological impact of TD most pronounced in adults under 60, with 77% of 18-29 year-olds experiencing moderate to severe effects.
The big picture
Teva's study underscores a critical gap in TD diagnosis among younger adults with mood disorders, highlighting both an unmet medical need and potential market opportunity for more targeted diagnostic tools and treatments. This aligns with broader industry trends toward personalized medicine and increased focus on neurological and psychiatric comorbidities. The findings may prompt regulatory scrutiny and push competitors to address similar diagnostic deficiencies in their patient populations.
What we're watching
- Diagnostic Improvement
- Whether Teva's findings will accelerate diagnostic protocols for younger patients with mood disorders and TD.
- Treatment Innovation
- How this data may influence development of targeted TD therapies for younger populations.
- Regulatory Impact
- The pace at which regulatory bodies may respond to address the identified diagnostic gaps in TD.
Related topics